Tag: therapeutic index
Kyowa Kirin Expands License Agreement with Synaffix
Japanese pharmaceutical and biotechnology company Kyowa Kirin has expanded its license agreement with The Netherlands based Synaffix with one new antibody-drug conjugates (ADC) target added to...
Pharmacokinetic Considerations to Maximize an ADC’s Therapeutic Index
The Antibody-drug Conjugate (ADC) field is poised for several significant advances in solid tumors as the industry has built upon knowledge gained over the...
Site Specific Conjugation of Hydrophobic Payloads Without Genetic Engineering
Site-specific conjugation leads to more homogeneous conjugates and allows control of the site of drug attachment. This approach frequently relies on antibody engineering to...
Understanding of the Underlying Mechanisms of Target-Independent Uptake and Toxicity
With 4 approved agents, antibody-drug conjugates or ADC have shown to be a very promising class of therapeutics.
While the concept of ADCs is not...
Synaffix ADCs Significantly Expands the Therapeutic Index vs Cysteine-Engineered ADCs
Netherlands-bases biotechnology company Synaffix BV, which exclusively focuses on the development of novel antibody-drug conjugate (ADC) technology, confirmed that a new set of head-to-head...
Site-specific Conjugation Based on Bacterial Transglutaminase Shows Improved Therapeutic Index of...
The key conclusion of these posters is that ADCs generated by BTG-ADC have improved pharmacokinetics and show a beter therapeutic index in in vivo models compared to brentuximab, with a significantly higher maximum tolerated dose (>60mg/kg vs 18 mg/kg) and a higher specific tumoral uptake.
